Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib

Thoracic Cancer

Volumn 6, Issue 6, 2015, Pages 695-703

  Li, Zhe ^a   Yang, Sheng Sheng ^b   Yin, Pei Hao ^c   Chang, Tao ^a   Shi, Lin Xiang ^a   Fang, Lin ^a   Fang, Guo En ^d  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acquired resistance; Breast cancer; ER; HER2; Lapatinib

Indexed keywords

CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR FKHRL1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 84945437977     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12239     Document Type: Article

References (28)

1. Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 2007; 7: 1183-1192.
2. Chan A. Lapatinib - Overview and current role in metastatic breast cancer. Cancer Res Treat 2006; 38: 198-200.
3. Campone M, Juin P, André F, Bachelot T. Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit Rev Oncol Hematol 2011; 78: 195-205.
4. Wang SE, Narasanna A, Perez-Torres etal. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25-38.
5. Burris HA 3rd, Hurwitz HI, Dees EC etal. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313.
6. Rexer BN, Ham AJ, Rinehart C etal. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011; 30: 4163-4174.
7. Yang CM, Lee IT, Lin CC, Wang CH, Cherng WJ, Hsiao LD. c-Src-dependent MAPKs/AP-1 activation is involved in TNF-alpha-induced matrix metalloproteinase-9 expression in rat heart-derived H9c2 cells. Biochem Pharmacol 2013; 85: 1115-1123.
8. Schlegel A, Wang C, Katzenellenbogen BS, Pestell RG, Lisanti MP. Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. Caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem 1999; 274: 33551-33556.
9. Long X, Fan M, Nephew KP. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant. Cancer Biol Ther 2010; 9: 389-396.
10. Pommier SJ, Quan GG, Christante D etal. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Ann Surg Oncol 2010; 17: 613-623.
11. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. (Published erratum appears in CA Cancer J Clin 2010; 61: 133-34) CA Cancer J Clin 2010; 60: 277-300.
12. Gomez HL, Doval DC, Chavez MA etal. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008; 26: 2999-3005.
13. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010; 7: 98-107.
14. MacFarlane RJ, Gelmon KA. Lapatinib for breast cancer: A review of the current literature. Expert Opin Drug Saf 2011; 10: 109-121.
15. Eichhorn PJ, Gili M, Scaltriti M etal. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230.
16. Xiang B, Chatti K, Qiu H etal. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci U S A 2008; 105: 12463-12468.
17. Xia W, Bacus S, Hegde P etal. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 2006; 103: 7795-7800.
18. Sergina NV, Rausch M, Wang D etal. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445: 437-441.
19. Liu L, Greger J, Shi H etal. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 2009; 69: 6871-6878.
20. Azuma K, Tsurutani J, Sakai K etal. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun 2011; 407: 219-224.
21. Bauerfeind I, Elling D, Heinemann V. Lapatinib in the treatment of hormone receptor-positive/ErbB2-positive breast cancer. Breast Care (Basel) 2010; 5 (Suppl. 1): 13-15.
22. Ritter CA, Perez-Torres M, Rinehart C etal. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13: 4909-4919.
23. Guo S, Sonenshein GE. Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 2004; 24: 8681-8690.
24. Park JH, Lee MY, Han HJ. A potential role for caveolin-1 in estradiol-17beta-induced proliferation of mouse embryonic stem cells: Involvement of Src, PI3K/Akt, and MAPKs pathways. Int J Biochem Cell Biol 2009; 41: 659-665.
25. Jin W, Wu L, Liang K, Liu B, Lu Y, Fan Z. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 2003; 89: 185-191.
26. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 2002; 21: 4000-4008.
27. Todorovic-Rakovic N, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D. Cross-talk between ER and HER2 in breast carcinoma. Archive of Oncology 2006; 14: 146-150.
28. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 2005; 67: 335-376.